[HTML][HTML] A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases

X Chen, J Han, J Chu, L Zhang, J Zhang, C Chen… - Oncotarget, 2016 - ncbi.nlm.nih.gov
X Chen, J Han, J Chu, L Zhang, J Zhang, C Chen, L Chen, Y Wang, H Wang, L Yi, JB Elder…
Oncotarget, 2016ncbi.nlm.nih.gov
Breast cancer brain metastases (BCBMs) are common in patients with metastatic breast
cancer and indicate a poor prognosis. These tumors are especially resistant to currently
available treatments due to multiple factors. However, the combination of chimeric antigen
receptor (CAR)-modified immune cells and oncolytic herpes simplex virus (oHSV) has not
yet been explored in this context. In this study, NK-92 cells and primary NK cells were
engineered to express the second generation of EGFR-CAR. The efficacies of anti-BCBMs …
Abstract
Breast cancer brain metastases (BCBMs) are common in patients with metastatic breast cancer and indicate a poor prognosis. These tumors are especially resistant to currently available treatments due to multiple factors. However, the combination of chimeric antigen receptor (CAR)-modified immune cells and oncolytic herpes simplex virus (oHSV) has not yet been explored in this context. In this study, NK-92 cells and primary NK cells were engineered to express the second generation of EGFR-CAR. The efficacies of anti-BCBMs of EGFR-CAR NK cells, oHSV-1, and their combination were tested in vitro and in a breast cancer intracranial mouse model. In vitro, compared with mock-transduced NK-92 cells or primary NK cells, EGFR-CAR-engineered NK-92 cells and primary NK cells displayed enhanced cytotoxicity and IFN-γ production when co-cultured with breast cancer cell lines MDA-MB-231, MDA-MB-468, and MCF-7. oHSV-1 alone was also capable of lysing and destroying these cells. However, a higher cytolytic effect of EGFR-CAR NK-92 cells was observed when combined with oHSV-1 compared to the monotherapies. In the mice intracranially pre-inoculated with EGFR-expressing MDA-MB-231 cells, intratumoral administration of either EGFR-CAR-transduced NK-92 cells or oHSV-1 mitigated tumor growth. Notably, the combination of EGFR-CAR NK-92 cells with oHSV-1 resulted in more efficient killing of MDA-MB-231 tumor cells and significantly longer survival of tumor-bearing mice when compared to monotherapies. These results demonstrate that regional administration of EGFR-CAR NK-92 cells combined with oHSV-1 therapy is a potentially promising strategy to treat BCBMs.
ncbi.nlm.nih.gov